In 1954, the 5, 5-diphenylimidazolidine nucleuses was found. It has a combined imidazolidine and dibenzene ring. Its structure resembles that of the medication phenytoin.1 Due to its numerous pharmaceutical applications, 5, 5-diphenylimidazolidine has significant heterocyclic nuclei. Scientist Brecker created the first 5, 5-diphenylimidazolidine in 1956.2 In Figure 1, 5, 5-diphenylimidazolidine was displayed. Today, the moiety of choice, 5, 5-diphenylimidazolidine, has a wide range of pharmacological characteristics.

The chemical compound 5, 5-diphenylimidazolidine-2,4-dione has a molecular weight of 252.273 and a chemical formula of C15H14N2O2. Since 1960, a substance with one imidazolidine and two benzene rings has been widely employed for pharmacological purposes. The active ingredients for numerous medications are composed of 5, 5-diphenylimidazolidine -2, 4-dione rings, which exhibit good outstanding basic properties since they contain 2 nitrogen atoms in their structure. Epidemiological studies indicate that 60 million people globally suffer from epilepsy, which is a prevalent condition of the brain.1–5 This number is increased by about 2,40,000 new cases per year.

Only 30% of patients with uncontrolled seizures have been cured despite the availability of more than 40 different anti-epileptic medications in the Indian market.1–9 As a result, research on antiepileptic compounds is currently quite active. The study of novel anti-convulsant drugs is the key focus. Based on the type of seizure, the identification of 5, 5-diphenylimidazolidine-2, 4-dione derivatives was done in vivo.10 The existence of an aryl binding site with an aryl/alkyl group, a hydrogen bonding domain, and an electron donor group are necessary conditions for potential anti-convulsant activity, and they all affect the anti-convulsant activity of various derivatives.11 Due to their structural resemblance to nucleobase and other heterocyclic building blocks, such as the 5, 5-diphenylimidazolidine-2, 4-dione derivative, which inhibits angiogenesis in vitro as well as in vivo biological activity, many heterocyclic building blocks have biological relevance. Therefore, the WHO and new scientists around the world have made substantial attempts to treat such convulsions, and numerous research groups have made efforts to discover novel anticonvulsant drugs. Contrarily, one of the most significant families of organic heterocyclic compounds with anticonvulsant therapeutic activity is represented pharmacologically by 5, 5-diphenylimidazolidine-2, 4-dione and its derivatives.12